BONESUPPORT HOLDING AB (BOEUF)

Overview

Bonesupport Holding AB (publ) stands out as a pioneering entity within the orthobiologics domain, primarily engaging in the development and global distribution of injectable bioceramic bone graft substitutes. Established in 1999 and based in Lund, Sweden, the company has effectively extended its reach beyond its European roots to make a significant impact in North America and other international markets. At its core, Bonesupport’s mission revolves around addressing the critical needs surrounding bone voids, catering to a diverse range of medical indications through its innovative solutions. This strategic focus not only places the company at the forefront of orthopedic care but also emphasizes its commitment to advancing medical technologies for bone regeneration and treatment.

Products and Services

Bonesupport Holding AB (publ) boasts a specialized portfolio of products designed to cater to the complex needs associated with bone void filling and regrowth. Each product is tailored to provide effective, patient-centric solutions for various orthopedic conditions:

• CERAMENT Bone Void Filler: This injectable, moldable, and drillable synthetic bone void filler is an ingenious concoction that integrates hydroxyapatite and calcium sulfate with the radio-contrast agent iohexol. It is specifically formulated to offer a versatile treatment option by mimicking the properties of natural bone, thereby facilitating effective bone void filling and regeneration in patients.
• CERAMENT G: As an augmentation to the foundational CERAMENT technology, CERAMENT G incorporates gentamicin into the ceramic bone graft substitute. This product is designed to provide not only the structural support necessary for bone regrowth but also an antibacterial component, making it especially beneficial in surgical interventions where infection poses a high risk. The incorporation of gentamicin positions CERAMENT G as a critical solution in orthopedic surgeries and treatments necessitating microbial protection.
• CERAMENT V: Similar in its design to CERAMENT G, CERAMENT V enriches the bioceramic bone graft substitute formula with vancomycin. This addition targets a broader spectrum of bacterial infections, particularly those that are difficult to treat, thus ensuring that the bone healing process is not compromised by infection. By combining the bone regenerative capabilities of CERAMENT with the potent antibacterial properties of vancomycin, CERAMENT V represents a significant advancement in the treatment of bone voids where infection control is paramount.

Alongside these products, Bonesupport is also at the forefront of developing preclinical candidates with the hope of further revolutionizing the treatment landscape for bone regeneration. This includes initiatives aimed at addressing trauma, revision arthroplasty, chronic osteomyelitis, as well as bone and foot infections associated with diabetes, thereby underscoring the company’s dedication to innovation and comprehensive care in the orthobiologics field.